The NFκB family is composed by five subunits (p65/RelA, c-Rel, RelB, p105-p50/ NFκB 1 , p100-p52/NFκB 2 ) and controls the expression of many genes that participate in cell cycle, apoptosis, and other key cellular processes. In a canonical pathway, NFκB activation depends on the IKK complex activity, which is formed by three subunits (IKKa and IKKb and IKKg/NEMO). There is an alternative NFκB activation pathway that does not require IKKb or IKKg/NEMO, in which RelB is a major player. We report in a panel of human breast cancer cells that the IKK/NFκB system is generally overexpressed in breast cancer cells and there is heterogeneity in expression levels of individual members between different cell lines. Doxorubicin, an anticancer agent used in patients with breast cancer, activated NFκB and appeared to be less effective in cells expressing predominantly members of the canonical IKK/NFκB. Two NFκB inhibitors, bortezomib and NEMO-Binding Domain Inhibitory Peptide, prevented doxorubicin-induced NFκB activation and increased doxorubicin antitumor effects in BT-474 cells. Transient down-regulation of members of the canonical pathway (p65, p52, c-Rel and IKKg/ NEMO) by siRNA in HeLa cells increased doxorubicin cytotoxicity. In contrast, silencing of RelB, a key subunit of the alternative pathway, had no evident effects on doxorubicin cytotoxicity. To conclude, NFκB inhibition sensitized cells to doxorubicin, implying directly p65, p52, c-Rel and IKKg/NEMO subunits in chemoresistance, but not RelB. These findings suggest that selective inhibition of the canonical NFκB pathway is sufficient to improve doxorubicin antitumor effects.
Preclinical and clinical data support a role for NFκB in the development and progression of human malignancies. 5 There is also increasing evidence that NFκB plays a role in chemoresistance. 6 Preclinical studies have shown that several chemotherapeutic agents activate the NFκB pathway. 7, 8 The resulting expression of anti-apoptotic proteins regulated by NFκB limits then the antitumor activity of cancer therapies. 9 We focused the present work in studying the role of NFκB in doxorubicin resistance for various reasons. First, doxorubicin is a chemotherapeutic agent from the anthracyclines group which is widely used for breast cancer treatment as well as in other malignancies. Anthracyclines are topoisomerase II inhibitors and produce DNA damage, that is a critical signal for NFκB activation. 10, 11 Furthermore, NFκB inhibition may enhance the cytotoxicity of anthracyclines. 12 In addition to experimental observations, we and others have reported that breast cancer patients with constitutively active NFκB in tumor cells were significantly more resistant to doxorubicin-based chemotherapy than patients with no basal NFκB activation. 12 We also found that NFκB appeared to be activable during chemotherapy exposure in some patients' tumors.
Intense efforts in the development of NFκB inhibitors for cancer treatment and particularly for reverting chemoresistance justify the need for further characterization and understanding of the NFκB pathway in human cancer. Here we show that there is a great diversity in the expression of individual members of the IKK/NFκB pathway in human breast cancer cells with a parallelism between a conserved expression of members of the canonical pathway and doxorubicin resistance. Notably, by using both pharmacological and genetic approaches, inhibition of the canonical NFκB pathway was sufficient to increase the cytotoxicity of doxorubicin.
MATeRIAlS AND MeThODS
Cell lines and cultures. Six human breast cancer cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-468, SK-BR-3, BT-474, MCF-7), a human cervical cancer cell line (HeLa) and a mammary epithelial one as control (MCF-10A) were purchased from the American Type Culture Collection and cultured at 37°C with 5% CO 2 in DMEM (MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-474, SK-BR-3, HeLa) or DMEM/F12 (MCF-7) supplemented with 2mM L-glutamine and 10% fetal bovine serum. For BT-474, insulin (0.01mg/ml) was added. Line MCF-10A was cultured in MEMB Basal Medium (Clonetics, cat. No. CC-3151) supplemented with MEGM Singlequots (Clonetics, cat. No. CC-4136): 2ml BPE, 500ng/ml hydrocortisone, 10ng/ml hEGF and 5mg/ml insulin. The rest of culture medium and supplements were obtained from Gibco-BRL.
Recombinant human TNFa was purchased from Calbiochem. Bortezomib was kindly provided by Millennium Pharmaceuticals (Cambridge, MA, USA); 10mM aliquots of drug in DMSO were stored at -20°C, thawed, and diluted just before use. NEMO-Binding Domain Inhibitory Peptide was purchased from Calbiochem (cat. No 480025). Doxorubicin (D1515) and all chemicals not otherwise specified below were purchased from Sigma.
MTS viability assay. The effects of doxorubicin on the proliferation and viability of breast cancer cells were studied using the colorimetric method provided by the MTS-CellTiter 96 Aqueous Non-Radiactive Cell Proliferation Assay Kit (Promega). MTS assay is a modification from MTT assay and depends on two solutions: a tetrazolium compound (MTS) and an electron coupling reagent (phenazine methosulfate; PMS). MTS is bioreduced by cells into a formazan product. The conversion of MTS into aqueous, soluble formazan is accomplished by dehydrogenase enzymes found in cells that are metabolically active. The quantity of formazan product as measured by the amount of 490 nm absorbance is directly proportional to the number of living cells in culture (21) . We performed the MTS assay in 96-well flat-bottomed plates (Nunc). Approximately 1 x 10 4 cells were seeded in 100 ml of drug free media and incubated for 24h before drug treatment. 100 ml of various 2x drug concentration (1x final concentration) were added for times from 24 to 48h. Forty microliters of MTS/PMS solution were added to the wells, and the cells were further incubated for 2-4h. The amount of soluble formazan produced, by cellular reduction of the MTS, was measured by the absorbance on a microplate spectrophotometer (Molecular Dynamics) at 490 nm (test wavelength) and 690 nm (reference wavelength). The percentage of surviving cells was estimated by dividing the A490-A690 nm of treated cells by the A490-A690 nm of control cells. Approximate IC 50 values were determined from the dose response curve. Data were derived from at least three independent experiments.
Western blot. For cytoplasmic western blot assays, cells were cultured in 6 well plates and lysed in ice-cold Nonidet P-40 buffer [1%NP40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, EDTA 5 mM containing 5 mM NaF, 2 mM Na 3 VO 4 , 1 mM PMSF, Leupeptin 5 mg/ml and Aprotinin 5 mg/ml]. After incubating for 30 min at 4°C, the samples were centrifuged, and the supernatant was kept as the NP-40-soluble fraction.
Nuclear cell extracts were obtained essentially as described in ref. 13 . Samples (10 mg/lane) were subjected to SDS-PAGE and transferred to nylon membranes (BioRad). Western blotting was carried out according to a standard procedure using horseradish peroxidase-conjugated secondary antibodies (Amersham). Target proteins were visualized after enhanced chemiluminescence treatment of membranes and subsequent exposure to X-ray film Electrophoretic mobility shift assay (EMSA). Nuclear extracts were obtained as for Western blotting described above. EMSAs were carried out with a 32 P-labeled NFκB and Oct1 probe using a Gel Shift Assay Core System kit (Promega), according to the manufacturer's instructions. 14 After electrophoresis, gels were fixed in 10% acetic acid-30% ethanol buffer during 15 min, and then dried under vacuum and exposed to X-ray film for three days. In some cases, a competition assay to determine sequence-specificity of protein-DNA interactions was performed by using 25-fold excess of unlabeled NFκB-probe. For supershift analysis, anti-p50 and anti-p65 antibodies were incubated with the nuclear extracts for 15 min prior to the addition of the radiolabeled probe. 15 Oligonucleotides used were: 5'-GGTGATG GATCTGAGTATA-3' for p52, 5'-CATACCCTTCTATCCAGAT-3 ' for c-Rel, 5'-TTG GAG ATC ATC GAC GAGT-3' for RelB and 5'-GATTGTGATGGAGACCGTT-3' for IKKg/NEMO. Bacterial colonies were pooled and used for plasmid preparation. Cells at 50% confluence were transfected with 6 mg of DNA using Lipofectamine 2000 Transfection Reagent (Invitrogen), according to the manufacturer's specifications. After three days, cells were subjected to Western blot analysis and MTS assay in the presence or absence of doxorubicin.
Immunofluorescence (IF
Statistical analysis. Statistical analysis was carried out with SPSS version 11.0 (SPSS, Inc, Chicago, IL). To analyze correlations the unpaired t test was used to determine the statistical differences. Statistical tests were conducted at the two-sided 0.05 level of significance. We then assayed by Western blot the expression of individual members of the IKK/NFκB system in our chosen panel of cell lines (Fig. 2) . Specifically, we assayed NFκB subunits (p65/Rel-A, p50-105/NFκB 1 , p52-100/NFκB 2 , c-Rel, RelB) ( Fig. 2A) , IKK complex isoforms (IKKa, IKKb and IKKg/NEMO) (Fig. 2B) , and NFκB inhibitory proteins (IκB-a, IκB-b, IκB-e) (Fig. 2C) . We also used a p65 antibody that recognizes the NLS of p65. Therefore, the antibody selectively binds to the presumably activated form of NFκB (here named as p65-NLS). IKK/NFκB proteins were generally overexpressed in malignant cell lines in comparison with the non-malignant cell line. All tumor cell lines had similar levels of p65. For other subunits, there were marked differences in protein expression levels between different cell lines. There was higher expression of activated p65-NLS in BT-474 cells in comparison with others. c-Rel and RelB, both with transactivation domain, and the inhibitory subunit p100 ( Fig. 2A, upper band) , had higher expression levels in MDA-MB-468 and SK-BR-3 cells, while p52 showed lower levels in SK-BR-3 and especially in MCF-7; subunit p50 was lower in BT-474 and p105 ( Fig. 2A, upper band) showed similar expression in all cell lines.
ReSulTS
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The expression of IKK complex isoforms also varied among cell lines. In some cells, a shorter (37 kDa) band was recognized by an anti-C-terminal IKKg/NEMO antibody independent of the presence of the native 50kDa band that corresponds to the full length IKKg/ NEMO protein. This 37kDa band was also detected with an anti-full length IKKg/NEMO antibody, but not with an antibody recognizing the N-terminal region of the protein (data not shown), further indicating that the 37 kDa band represents an IKKg/NEMO fragment with a truncated N-terminus rather than C-terminus. Nevertheless, both Northern blot and RT-PCR assays (data not shown) detected only one mRNA size for IKKg/NEMO, suggesting the possibility that the shorter protein IKKg/NEMO isoform is generated by a post-translational event. Expression of inhibitory IκBs proteins showed that IκB-a was higher in MDA-MB-453, SK-BR-3, BT-474 and MCF-7. IκB-b was undetected in MDA-MB-468 and IκB-e expression was similarly expressed in all malignant cell lines.
These results show heterogeneity in the expression of individual members of the IKK/NFκB pathways. A lower expression of members of the alternative NFκB pathway, p100 and RelB, was observed in two cell lines, BT-474 and MCF-7. Globally, it appeared that cell lines with a predominant expression of members of the canonical pathway, such as BT-474 and MCF-7, were less sensitive to doxorubicin. However, this correlation could be merely coincidental.
Inhibition of NFκB by bortezomib and NBD inhibitory peptide enhanced doxorubicin sensivity in BT-474 Cells. The next set of experiments was focused in studying a possible NFκB involvement in the resistance to doxorubicin. For these experiments, BT-474 cells were chosen because were relatively resistant to doxorubicin in our panel, had a predominant expression of members of the canonical pathway and also showed a greater expression of NLSp65 subunit. In a first step, NFκB-DNA binding activity following doxorubicin treatment was analyzed by EMSA. BT-474 cells were treated with 15 mM doxorubicin or with 10 ng/ml TNFa (as a positive control). These conditions were chosen after performing time-response assays and selecting the doxorubicin concentration at its IC 25 . Both TNFa and doxorubicin induced a marked NFκB DNA binding compared with untreated cells (Fig. 3A) . Specificity was verified by competition with a 25-fold excess of unlabeled NFκB-probe. As shown in Figure 3A , the indicated NF NFκB-DNA complexes were substantially -DNA complexes were substantially removed by adding an excess of cold NF NFκB probe (specific probe).
probe (specific probe).
Similar levels of the control oligonucleotide for Oct1 binding in the different samples confirm that the observed differences in NFκB activity are not due to differences in activity are not due to differences in the integrity of nuclear extract used in this experiment. Additionally, EMSA supershift assay, with specific NFκB subunits antibodies, showed that doxorubicin-induced NFκB contains at least the p50 and p65 subunits; two specific bands could be identified: the lower band as the p50/p50 homodimer and the upper band as the p50/ p65 heterodimer (Fig. 3B) . Experiments xperiments of p65 and p50 co-localization were also co-localization were also performed by IF. The p65-p50 complexes . The p65-p50 complexes (identified as yellow merged signals) were detected in most of TNFa or doxorubicin treated cells (Fig. 3C) . .
We then studied whether blocking NFκB activation could improve doxorubicin effects on cytotoxicity. To perform these studies we used two different NFκB inhibitors that act at different levels on the NFκB pathway: BTZ, a proteasome inhibitor [16] [17] [18] that prevents IκB-a degradation, and therefore keeps NFκB dimers at the cytoplasm; and a NEMO-binding domain-(NBD) inhibitory peptide, which consists on an amino-terminal a-helical region of IKKg/NEMO associated with a carboxy-terminal segment of IKKa and IKKb, that it blocks the IKK complex formation. 19, 20 Molecular effects of both NFκB inhibitors were assayed by Western blot. For these experiments, NFκB activation was assayed using an antibody specific for phosphorylated p65 (P-p65). p65 is phosphorylated in Ser536 in the C-terminal transactivation domain during the phosphorylation and degradation of IκBs. Doxorubicin treatment resulted in both p65 phosphorylation and IκB-a degradation (Fig. 4A ). Cells were treated with 1 mM BTZ or with 10 mM NBD-inhibitory peptide for 90 min, and then exposed to 15 mM doxorubicin or 10 ng/ml TNFa for 4 h. Pre-incubation with BTZ (Fig. 4B) or NBD-inhibitory peptide (Fig. 4C ) prevented doxorubicin induced p65 phosphorylation.
Cotreatment of BT-474 cells with doxorubicin and with NBD or BTZ reduced cell viability to a greater extent than doxorubicin alone, NBD alone or BTZ alone. NFκB implication in cellular doxorubicin resistance was shown when BT-474 cells were treated with doxorubicin combined or not with NFκB inhibitors for 48 h and revealed in a MTS assay (Fig. 4D ). The combination with BTZ or NBD-inhibitory peptide enhanced by 30% and 40%, respectively, doxorubicin cytotoxicity. Notably, NBD-inhibitory peptide plus doxorubicin resulted in greater effects on cell viability than bortezomib plus doxorubicin. The observations that NBD-inhibitory peptide had only slight effects on cell viability when used alone, while it markedly enhanced the effects on doxorubicin, supported a role of NEMO in mediating doxorubicin resistance under our assayed conditions. pathway and the chemosensitization obtained by NBD-inhibitory peptide (which should affect only the activation of the canonical pathway), suggested that the canonical pathway was involved in doxorubicin resistance. In an attempt to further understand the role of individual IKK/NFκB subunits in doxorubicin resistance, siRNA oligonucleotides were designed for selected proteins of the pathway. For this purpose, HeLa cells were chosen for the siRNA assays due to their high transfection efficiency compared with the poor efficiency achieved in BT-474 cells (data not shown). HeLa cells are derived from cervix carcinoma, a tumor type also treatable with doxorubicin. Activation of NFκB in HeLa cells exposed to doxorubicin was observed. A 4 h treatment with doxorubicin induced p65 phosphorylation and concomitant IκB-a degradation in HeLa cells (Fig. 5A) . NFκB subunits (p65, c-Rel, RelB, p50, p52, p105) were assayed by Western blot in HeLa nuclear extracts treated with doxorubicin or TNFa (positive control) (Fig. 5B) . All subunits were detected in the nucleus in response to doxorubicin or TNFa exposure in a higher extent that in control cells.
The efficiency of the designed siRNA oligonucleotides was tested by Western blot. Cells were transfected with different DNA amounts and lysed at different times to find out the best combination. A decrease of protein levels of the corresponding NFκB subunits was observed after three days of transfection with 6 mg of the corresponding siRNA vector (Fig. 6A) .
We next performed viability assays, in which cells were transfected with the respective siRNA, kept resting and three days later treated with doxorubicin for 24 h. siRNA transfected cells did not exhibit evident effects on cell viability versus empty vector transfected cells. Transient silencing of p65, p52, c-Rel or IKKg/NEMO enhanced approximately by 30% the cytotoxicity of doxorubicin (% cell viability: control p65 84.2% ± 6.6%, p65 51.5% ± 3.1%; control pSUPER 85.9% ± 3.5%, p52 51.4% ± 1.6%, c-Rel 59.8% ± 2.18%, IKKg/NEMO 53% ± 1.9%)(p < 0.05, data not shown). However, silencing RelB subunit, which only participates in the non canonical NFκB pathway, had much less effect on doxorubicin cytotoxicity (cell viability of 78% ± 7.55%) (Fig. 6B) .
DISCuSSION
In the present work we observed diversity in the expression of individual members of the IKK/NFκB pathway among different human breast cancer cell lines. A possible link between predominant expression of members of the canonical pathway and doxorubicin resistance was suggested from these studies. Furthermore, inhibition of the canonical NFκB pathway was sufficient to increase doxorubicin cytotoxicity in two different human tumor cell types (breast and cervix carcinomas) as assayed by a pharmacological and a genetic approach.
NFκB activation is a frequent event mediated by many chemotherapeutic agents, 21 which commonly implies the induction of a strong anti-apoptotic response that limits the efficacy of the treatment. 1 The same mechanism of resistance can occur with hormonal treatments and with radiation therapy. 8, 22 We aimed our studies to gain further insight in the relationship between IKK/NFκB expression/activation and the cytotoxicity of doxorubicin in two human cancer types where this agent is employed in clinical settings. It is well known that anthracyclines, such as doxorubicin, target DNA topoisomerase II resulting in DNA damage, a critical signal to switch on NFκB. 10 Moreover, it has been previously reported that in response to double strand DNA breaks IKKg/NEMO is retained in the nucleus, where it is modified by SUMO and phosphorylated by the ATM kinase, 23 then it translocates to the cytoplasm and joins IKKb and IKKa for IKK complex formation and NFκB activation. 24, 25 Consequently, it was hypothesized that doxorubicin efficiency could be augmented by repressing the activation of NFκB. Along this line, it has been described that NFκB inhibition sensitizes tumour cells to anthracyclines therapy 26 and more specifically to doxorubicin treatment. 7, [27] [28] [29] From a clinical perspective, we recently showed that activation of NFκB, determined by NFκB/p65 nuclear immunostaining in tumor cells, significantly correlated with resistance to anthracycline-based chemotherapy in breast cancer patients. 12 Furthermore, the number of patients with NFκB/p65 activation increased after chemotherapy exposure. That study revealed a link between activation of the canonical pathway (using nuclear p65 translocation as a surrogate marker of activation) and resistance to anthracyclines. Other elegant studies have reported similar findings in breast cancer as well as in other tumor types. 6, 7, 30 Notably, NFκB/ bcl-2 pathway has been shown to correlate with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. 6 These novel in vivo data strongly supported a role of NFκB activation, and in particular of the canonical pathway, as a cellular mechanism of resistance to anticancer therapy and suggested that NFκB/p65 was inducible by chemotherapy in patients.
We assayed the expression of most of the proteins participating in the IKK/NFκB pathways; the five NFκB members, the three IKK isoforms, and three of the inhibitory IκBs. Many of these proteins were overexpressed in breast cancer cell lines compared to the nonmalignant breast epithelial cell line MCF-10A. In addition, there was heterogeneity among different cell lines. MCF-10A cells, as assayed by MCF-10A cells, as assayed by MTS, had an intermediate degree of sensitivity to doxorubicin with regards to our panel of malignant breast cancer cell lines. This result is similar (i.e., viability of MCF-10A cells affected by anticancer drugs to a similar extend than some malignant cells) to findings using other agents. 31 Although this part of the work was merely descriptive, it Although this part of the work was merely descriptive, it raised several observations of potential importance for future studies. First, the molecular mechanisms underlying the overexpression or the downmodulation (even to undetected levels) of key proteins of this system are largely unknown. In particular, a shorter form for IKKg/NEMO (~37 KDa) was detected in some lines by both an anti-full length IKKg/NEMO antibody and an anti C-terminal antibody, while another antibody against the N-terminal extreme did not detected it. On the other hand, both Northern Blot and RT-PCR assays revealed a single mRNA size for IKKg/NEMO. Altogether, these experiments suggest the possibility of a new short form for IKKg/NEMO protein as a result of post-translational processing. Second, two cell lines, MCF-7 and BT-474 had a conserved expression of all the key members of the canonical pathway assayed. These two cell lines were relatively resistant to doxorubicin, thus indirectly suggesting that the integrity of the canonical pathway might be related to resistance to this agent. Due to these findings, we focused our additional studies in BT-474 breast cancer cells. In BT-474 cells, doxorubicin promoted IκB-a degradation, concomitantly with p65 phosphorylation, and induction of NFκB DNA binding. We then investigated the chemosensitizing effects of two different NFκB inhibitors; BTZ and NBD-inhibitory peptide. The first agent, BTZ, is a proteasome inhibitor already approved in approved in many countries for the treatment of patients with multiple myeloma and in further clinical development in multiple tumor types. The role of BTZ in NFκB inhibition is indirect and mediated by its effect in the canonical pathway. Proteasome inhibition prevents IκB degradation and therefore abrogates p65 nuclear translocation. However, BTZ affects many other key intracellular proteins and therefore the effects on NFκB are not the sole mechanism of antitumor action of this agent. In a previous study we also found that MCF-7 and BT-474 cells were the most resistant to BTZ. 18 We also investigated here the effects of NEMO-binding domain-(NBD) inhibitory NEMO-binding domain-(NBD) inhibitory peptide, which selectively blocks the canonical pathway by disrupting the IKK complex. Both agents, BTZ and NBD-inhibitory peptide, augmented doxorubicin cytotoxic effects by 30% to 40% under our experimental conditions. Thus, NFκB inhibitors improved doxorubicin treatment in BT-474 breast cancer cells, which adds additional support to the hypothesis of the NFκB pathway as involved in tumor resistance to doxorubicin, and pointed to a key role of the canonical pathway in this effect. We cannot rule out that effects other than NFkB inhibition contribute to this enhanced tumorocidal effect, since both NBD inhibitory peptide and BTZ when used alone reduced cell viability. However, the effects of NBD inhibitory peptide on cell viability were modest while it greatly enhanced doxorubicin effects.
We next performed small interference RNA experiments in HeLa cells to explore the role of individual members on doxorubicin response. We confirmed that doxorubicin induced IκB-a degradation and p65 phosphorylation, together with nuclear translocation of NFκB subunits (p65, c-Rel, RelB, p50, p52 and p105). siRNA assays against the selected NFκB proteins -p65, p52, c-Rel-as well as with IKKg/NEMO, increased about 30-40% doxorubicin cytotoxicity. The death increase obtained by silencing p52 is in line with a recent publication, 32 which describes that p52/RelB heterodimers only participate in the alternative pathway, while p52/p65 or p52/c-Rel heterodimers are controlled by IκB inhibitors and finally activated by the IKK complex in the canonical pathway. In contrast, silencing RelB, which participates selectively in the alternative NFκB pathway, had only minor effects on doxorubicin cytotoxicity. Preliminary experiments using siRNA constructions in combination with another chemotherapeutic agent widely used, docetaxel (Taxotere), which is also known to activate NFκB, 7 suggested similar results (data not shown). Our results indicate that selective inhibition of the chosen subunits of the classical IKKNFκB pathway was sufficient to increase doxorubicin antitumor effects. The work presented here reveals diversity in expression of individual members of the IKK/NFκB pathway among different human breast cancer cell lines. This observation raises additional support to the need of further functional studies as well as assays in tumor samples from patients. From a functional perspective, inhibition of the canonical NFκB pathway was sufficient to increase the cytotoxicity of doxorubicin in two different human tumor cell types (breast and cervix carcinomas) as shown by two approaches (pharmacological and genetic). These findings show that selective inhibition of the canonical IKKNFκB pathway is sufficient to improve doxorubicin antitumor effects in the studied models, an observation that should be taken into account for further development of IKK/NFκB inhibitors as chemosensitizing agents. 
